ACP
CMPX icon

Acuta Capital Partners’s Compass Therapeutics CMPX Stock Holding History

Acuta Capital Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
595,213
-253,863
-30% -$749K 0.91% 20
2026
Q1 		$4.49M Sell
849,076
-244,224
-22% -$1.41M 3.17% 10
2025
Q4 		$5.87M Buy
1,093,300
+253,210
+30% +$1.17M 3.99% 7
2025
Q3 		$2.94M Buy
+840,090
New +$2.65M 3.04% 11

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acuta Capital Partners's CMPX Position: Q2 2026 in Review

Acuta Capital Partners reduced its Compass Therapeutics (CMPX) stake by 30% in Q2 2026, selling an estimated $749K and leaving 595,213 shares worth $1.3M. The position accounts for 0.91% of the portfolio, ranked #20.

Acuta Capital Partners first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.87M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Acuta Capital Partners held 595,213 shares of Compass Therapeutics worth $1.3M as of Q2 2026.
  • Acuta Capital Partners sold 253,863 Compass Therapeutics shares in Q2 2026, an estimated $749K.
  • Compass Therapeutics made up 0.91% of Acuta Capital Partners's portfolio in Q2 2026, its #20 holding.
  • Acuta Capital Partners first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Acuta Capital Partners's Compass Therapeutics position peaked at $5.87M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.